Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Apolipoprotein M - a marker or an active player in type II diabetes?

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Levothyroxine Therapy in Elderly Patients With Hypothyroidism

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Effects of endogenous GIP in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Danish comorbidity in liver transplant recipients study (DACOLT): a non-interventional prospective observational cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reduced erythrocyte lifespan measured by chromium-51 in patients with type 2 diabetes undergoing long-term hemodialysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts. Calcitonin of mammalian origin promotes insulin sensitivity, while the more potent calcitonin extracted from salmon additionally inhibits gastric emptying, promotes gallbladder relaxation, increases energy expenditure and induces satiety as well as weight loss. Amylin, derived from pancreatic beta cells, regulates plasma glucose by delaying gastric emptying after meal ingestion, and modulates glucagon secretion and central satiety signals in the brain. Thus, both hormones seem to have metabolic effects of relevance in the context of non-alcoholic fatty liver disease (NAFLD) and other metabolic diseases. In rats, studies with dual amylin and calcitonin receptor agonists have demonstrated robust body weight loss, improved glucose tolerance and a decreased deposition of fat in liver tissue beyond what is observed after a body weight loss. The translational aspects of these preclinical data currently remain unknown. Here, we describe the physiology, pathophysiology, and pharmacological effects of amylin and calcitonin and review preclinical and clinical findings alluding to the future potential of amylin and calcitonin-based drugs for the treatment of obesity and NAFLD.

OriginalsprogEngelsk
Artikelnummer617400
TidsskriftFrontiers in Endocrinology
Vol/bind11
Sider (fra-til)617400
ISSN1664-2392
DOI
StatusUdgivet - 8 jan. 2021

Bibliografisk note

Copyright © 2021 Mathiesen, Lund, Vilsbøll, Knop and Bagger.

ID: 62046961